Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003906 · ClinicalTrials.gov registry record · Phase 3
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
A Phase 3 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 19,747
- Enrollment target
NCT00003906 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 19,747 participants.
The verdict
NCT00003906, a Phase 3 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19,747 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized double-blinded clinical trial to compare the effectiveness of raloxifene with that of tamoxifen in preventing breast cancer in postmenopausal women.
Interventions
- DRUG Tamoxifen
- DRUG Raloxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,747 participants |
| Start Date | 1999-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003906
The ClinicalTrials.gov registry entry for NCT00003906 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19,747 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT00003906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003906 about?
NCT00003906 is a clinical study titled "Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized double-blinded clinical trial to compare the effectiveness of raloxifene with that o...
What is the current status of trial NCT00003906?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19,747 participants. The study started on 1999-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00003906?
The interventions under investigation include: Tamoxifen (DRUG), Raloxifene (DRUG).
Who is sponsoring clinical trial NCT00003906?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.